These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 17367501)

  • 1. Blocking translocation of cell surface molecules from the ER to the cell surface by intracellular antibodies targeted to the ER.
    Böldicke T
    J Cell Mol Med; 2007; 11(1):54-70. PubMed ID: 17367501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific in vivo knockdown of protein function by intrabodies.
    Marschall AL; Dübel S; Böldicke T
    MAbs; 2015; 7(6):1010-35. PubMed ID: 26252565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Advances with ER Targeted Intrabodies.
    Marschall AL; Dübel S; Böldicke T
    Adv Exp Med Biol; 2016; 917():77-93. PubMed ID: 27236553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional inhibition of transitory proteins by intrabody-mediated retention in the endoplasmatic reticulum.
    Böldicke T; Somplatzki S; Sergeev G; Mueller PP
    Methods; 2012 Mar; 56(3):338-50. PubMed ID: 22037249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracellular antibodies (intrabodies) and their therapeutic potential.
    Lo AS; Zhu Q; Marasco WA
    Handb Exp Pharmacol; 2008; (181):343-73. PubMed ID: 18071953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intradiabodies, bispecific, tetravalent antibodies for the simultaneous functional knockout of two cell surface receptors.
    Jendreyko N; Popkov M; Beerli RR; Chung J; McGavern DB; Rader C; Barbas CF
    J Biol Chem; 2003 Nov; 278(48):47812-9. PubMed ID: 12947084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracellular antibodies (intrabodies) versus RNA interference for therapeutic applications.
    Cao T; Heng BC
    Ann Clin Lab Sci; 2005; 35(3):227-9. PubMed ID: 16081577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel highly efficient intrabody mediates complete inhibition of cell surface expression of the human vascular endothelial growth factor receptor-2 (VEGFR-2/KDR).
    Böldicke T; Weber H; Mueller PP; Barleon B; Bernal M
    J Immunol Methods; 2005 May; 300(1-2):146-59. PubMed ID: 15946674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional knock down of VCAM1 in mice mediated by endoplasmatic reticulum retained intrabodies.
    Marschall AL; Single FN; Schlarmann K; Bosio A; Strebe N; van den Heuvel J; Frenzel A; Dübel S
    MAbs; 2014; 6(6):1394-401. PubMed ID: 25484057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Making cell-permeable antibodies (Transbody) through fusion of protein transduction domains (PTD) with single chain variable fragment (scFv) antibodies: potential advantages over antibodies expressed within the intracellular environment (Intrabody).
    Heng BC; Cao T
    Med Hypotheses; 2005; 64(6):1105-8. PubMed ID: 15823695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Intrabodies, potent tools to unravel the function and dynamics of intracellular proteins].
    Moutel S; Perez F
    Med Sci (Paris); 2009 Dec; 25(12):1173-6. PubMed ID: 20035701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. beta-site specific intrabodies to decrease and prevent generation of Alzheimer's Abeta peptide.
    Paganetti P; Calanca V; Galli C; Stefani M; Molinari M
    J Cell Biol; 2005 Mar; 168(6):863-8. PubMed ID: 15767460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineering a growth sensor to select intracellular antibodies in the cytosol of mammalian cells.
    Nguyen TD; Takasuka H; Kaku Y; Inoue S; Nagamune T; Kawahara M
    J Biosci Bioeng; 2017 Jul; 124(1):125-132. PubMed ID: 28319021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies inside of a cell can change its outside: Can intrabodies provide a new therapeutic paradigm?
    Marschall AL; Dübel S
    Comput Struct Biotechnol J; 2016; 14():304-8. PubMed ID: 27570612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 envelope protein is expressed on the surface of infected cells before its processing and presentation to class II-restricted T lymphocytes.
    Callahan KM; Rowell JF; Soloski MJ; Machamer CE; Siliciano RF
    J Immunol; 1993 Sep; 151(6):2928-42. PubMed ID: 8376762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A protein silencing switch by ligand-induced proteasome-targeting intrabodies.
    Melchionna T; Cattaneo A
    J Mol Biol; 2007 Nov; 374(3):641-54. PubMed ID: 17950312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of functional scFv intrabodies for triggering anti-tumor immunity.
    Bonnin E; Gruel N; Moutel S; Mantegazza AR; Barrio MM; Mordoh J; Teillaud JL
    Methods; 2004 Oct; 34(2):225-32. PubMed ID: 15312675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanobodies Right in the Middle: Intrabodies as Toolbox to Visualize and Modulate Antigens in the Living Cell.
    Wagner TR; Rothbauer U
    Biomolecules; 2020 Dec; 10(12):. PubMed ID: 33371447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-translational selective intracellular silencing of acetylated proteins with de novo selected intrabodies.
    Chirichella M; Lisi S; Fantini M; Goracci M; Calvello M; Brandi R; Arisi I; D'Onofrio M; Di Primio C; Cattaneo A
    Nat Methods; 2017 Mar; 14(3):279-282. PubMed ID: 28092690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracellular antibodies (intrabodies) for gene therapy of infectious diseases.
    Rondon IJ; Marasco WA
    Annu Rev Microbiol; 1997; 51():257-83. PubMed ID: 9343351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.